[1] Bellot P, Franc R,Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int,2013,33:31-39.
[2] D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol,2006,44:217-231.
[3] Burge S, White D, Bajorek E, et al. Correlates of medication knowledge and adherence: findings from the residency research network of South Texas. Fam Med,2005,37:712-718.
[4] Lim YS,Kim WR. The global impact of hepatic fibrosis and endstage liver disease. Clin Liver Dis,2008,12:733-746.
[5] Fallis BA, Dhalla IA, Klemensberg J,et al. Primary medication nonadherence after discharge from a general internal medicine service. PLoS One,2013,8:e61735.
[6] Kimer N, Krag A,Gluud LL. Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy. Patient Prefer Adherence,2014,8:331-338.
[7] Leevy CB,Phillips JA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci,2007,52:737-741.
[8] Barber N, Safdar A, Franklin BD. Can human error theory explain nonadherence? Pharm World Sci, 2005, 27:300-304.
[9] Les I, Doval E, Flavia M, et al. Quality of life in cirrhosis is related to potentially treatable factors. Eur J Gastroenterol Hepatol, 2001,22:221-227.
[10] Sola E, Watson H, Graupera I, et al. Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema. J Hepatol,2012,57:1199-1206.
[11] Younossi ZM, Boparai N, Price LL, et al. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol,2001,96:2199-2205.
[12] Les I, Doval E, Flavia M, et al. Quality of life in cirrhosis is related to potentially treatable factors. Eur J Gastroenterol Hepatol, 2010,22:221-227. |
